Novartis AG (NVS)


NYSE - NYSE Real Time Price. Currency in USD
79.64+0.33 (+0.42%)
At close: 4:02 PM EDT
People also watch:
GSKSNYAZNLLYABT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open79.45
Prev Close79.31
Bid79.52 x 100
Ask79.77 x 100
Day's Range79.21 - 79.79
52wk Range69.90 - 98.95
1y Target EstN/A
Market Cap189.64B
P/E Ratio (ttm)28.43
Beta0.64
Volume650,435
Avg Vol (3m)1,467,157
Dividend & Yield2.72 (3.43%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Here’s What’s Important With The Novartis AG (ADR) (NVS) MS Data
    Insider Monkey14 hours ago

    Here’s What’s Important With The Novartis AG (ADR) (NVS) MS Data

    Novartis AG (ADR) (NYSE:NVS) just put out data from its multiple sclerosis (MS) trial, and it looks as if the company is winning the race to bring a drug to market that offers a solution for patients with secondary progressive MS (SPMS), a severe form of the condition. Biogen Inc (NASDAQ:BIIB) is also working on […]

  • Benzinga14 hours ago

    Almost The Whole World In This ETF's Hands

    Investors looking for total market exposure excluding U.S. stocks have a myriad of options in the world of exchange traded funds. One of the more well-known options is the iShares MSCI ACWI ex US Index ...

  • Novartis AG (NVS) Announces Positive Phase III Results For MS Drug
    Insider Monkey3 days ago

    Novartis AG (NVS) Announces Positive Phase III Results For MS Drug

    Novartis AG (NYSE:NVS) has announced that the Phase III EXPAND study, which is evaluating the efficacy and safety of oral, once daily, BAF312 in secondary progressive multiple sclerosis (SPMS), has met its primary endpoint of reducing the risks of disability progression, compared with placebo. The EXPAND study represented the largest randomized, controlled study in SPMS to date. It […]